{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076522","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.980105+00:00","generated_at":"2026-05-15T23:29:35.677852+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M","bullets":["Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.","Revuforj net revenue $44.2M in Q4 (+38% vs Q3) and $124.8M in FY2025; ~1,150 prescriptions in Q4.","Niktimvo net revenue $56M in Q4 (+22% vs Q3) and $151.6M in FY2025; Syndax collaboration revenue $42.4M FY.","Net loss $68M (0.78/share) in Q4 and $285.4M ($3.29/share) for FY2025; cash $394.1M at year-end.","FY2026 opex guidance ~$400M ex-stock comp; expects profitability from cash, revenue, and interest income."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076522","json":"https://secwatch.observer/filing/0001193125-26-076522.json","markdown":"https://secwatch.observer/filing/0001193125-26-076522.md","text":"https://secwatch.observer/filing/0001193125-26-076522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/0001193125-26-076522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:29:35.677852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}